Results 141 to 150 of about 242 (180)
Some of the next articles are maybe not open access.

Related searches:

Efectos cardioprotectores del ticagrelor

Revista Española de Cardiología Suplementos, 2017
El desarrollo de los inhibidores del receptor plaquetario P2Y12 ha sido fundamental para el tratamiento de los pacientes con sindrome coronario agudo. En los ultimos anos, multiples evidencias experimentales y clinicas sustentan que los inhibidores del receptor P2Y12 ejercen efectos pleotropicos mas alla de sus propiedades antiagregantes plaquetarias ...
Lina Badimona, Gemma Vilahur
openaire   +1 more source

Purpurogallin: In vivo evidence of a novel and effective cardioprotector

Life Sciences, 1994
We observed that purpurogallin (PPG) which is a flavonoid markedly protects the rabbit against myocardial ischemia-reperfusion injury. In rabbits undergoing 1-h ligation of the anterior ventricular coronary artery, a bolus infusion of PPG was introduced into the post-ischemic heart immediately before 3-h reperfusion.
T W, Wu   +5 more
openaire   +2 more sources

Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?

Cardiovascular & Hematological Disorders-Drug Targets, 2006
Beta-blockers have been used to treat ischemic heart disease, due to negative chronotropic and inotropic properties, thus inducing a decrease in myocardial consumption of oxygen and nutrients, allowing a better balance between nutritional needs and the supply provided by the coronary blood flow.
R S, Carreira   +3 more
openaire   +2 more sources

Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection

Recent Patents on Biotechnology, 2017
Cardiovascular diseases are a group of disorders of the heart and blood vessels that account for a major cause of premature death worldwide. Diosgenin saponin is a steroid for therapeutic application in different clinical settings such as cardiovascular diseases, hyperglycemia and dyslipidemia control, antimicrobial, anti-viral and anti-inflammatory ...
Michely Laiany Vieira, Moura   +2 more
openaire   +2 more sources

Insulin: an endogenous cardioprotector

Current Opinion in Critical Care, 2003
This review discusses the myocardial protective property of the insulin/glucose-insulin-potassium regimen and the mechanisms involved in this beneficial action. Several recent studies suggest that insulin not only is useful to control hyperglycemia and maintain glucose homeostasis but also may have the unique property to protect the myocardium from ...
openaire   +2 more sources

The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice

Cancer Chemotherapy and Pharmacology, 2003
Monohydroxyethylrutoside (monoHER) has proved to be a good protector against doxorubicin-induced cardiotoxicity without interfering with the antitumor effect of doxorubicin. The aim of the present study was to determine whether there is a pharmacokinetic interaction between monoHER and doxorubicin which may be involved in monoHER cardioprotection.Mice ...
Abou el Hassan, M.A.   +4 more
openaire   +3 more sources

Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose Doxorubicin

JNCI Journal of the National Cancer Institute, 1992
Although doxorubicin is an anticancer agent with a wide spectrum of activity, therapy with this anthracycline must often be discontinued at a time of benefit to the patient because of the drug's cumulative cardiotoxicity. ICRF-187 (ADR-529, dexrazoxane) is a bisdioxopiperazine compound that protects against cardiac toxicity induced by doxorubicin.Our ...
H, Hochster   +8 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy